Sensus Healthcare Inc (SRTS)
Official siteHEALTHCARE • MEDICAL DEVICES • NASDAQ
Market Cap: $38.27M
Last updated: Nov 17, 2026 at 11:05 AM ET
Sensus Healthcare Inc (SRTS) Earnings: Report Dates and Results
Sensus Healthcare (SRTS) is expected to report earnings on Feb 10, 2027. In the quarter ended Sep 30, 2026, Sensus Healthcare reported EPS of -$0.09, below the -$0.04 estimate. It beat the EPS estimate in 1 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
SRTS has an expected report date of Feb 10, 2027.
SRTS Earnings Call
The latest SRTS earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 39 quarters below that had an estimate, SRTS beat 22, missed 15 and matched 2. Revenue for the quarter ended Sep 30, 2026 was $6.00M, down 12.8% from $6.88M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$0.09 | -$0.04 | -$0.08 - $0.02 | -107.85% | Miss | N/A | 3 | 0 up, 0 down | Nov 12, 2026 | $6.00M |
| Jun 30, 2026 | -$0.18 | -$0.11 | -$0.15 - -$0.09 | -63.64% | Miss | N/A | 3 | 0 up, 2 down | Aug 13, 2026 | $2.29M |
| Mar 31, 2026 | -$0.16 | -$0.11 | -$0.12 - -$0.10 | -45.45% | Miss | N/A | 3 | 0 up, 2 down | May 7, 2026 | $3.39M |
| Dec 31, 2025 | -$0.19 | -$0.05 | -$0.06 - -$0.05 | -280.00% | Miss | -311.1% | 2 | 0 up, 0 down | Feb 12, 2026 | $4.94M |
| Sep 30, 2025 | -$0.06 | -$0.11 | -$0.13 - -$0.08 | +45.45% | Beat | -185.7% | 3 | 0 up, 0 down | Nov 6, 2025 | $6.88M |
| Jun 30, 2025 | -$0.06 | $0.01 | -$0.01 - $0.03 | -700.00% | Miss | -160.0% | 3 | 1 up, 3 down | Aug 7, 2025 | $7.32M |
| Mar 31, 2025 | -$0.16 | $0.04 | -$0.01 - $0.04 | -500.00% | Miss | -214.3% | 4 | 0 up, 1 down | May 15, 2025 | $8.34M |
| Dec 31, 2024 | $0.09 | $0.12 | $0.09 - $0.14 | -25.00% | Miss | -65.4% | 4 | 0 up, 2 down | Feb 5, 2025 | $13.07M |
| Sep 30, 2024 | $0.07 | -$0.01 | -$0.02 - -$0.01 | +800.00% | Beat | N/A | 2 | 1 up, 0 down | Nov 14, 2024 | $8.84M |
| Jun 30, 2024 | $0.10 | $0.03 | $0.02 - $0.03 | +233.33% | Beat | N/A | 3 | 1 up, 0 down | Aug 8, 2024 | $9.24M |
| Mar 31, 2024 | $0.14 | -$0.04 | -$0.07 - -$0.04 | +450.00% | Beat | N/A | 2 | 0 up, 0 down | May 9, 2024 | $10.66M |
| Dec 31, 2023 | $0.26 | $0.14 | $0.04 - $0.19 | +85.71% | Beat | +52.9% | 5 | 4 up, 0 down | Feb 8, 2024 | $12.57M |
| Sep 30, 2023 | -$0.09 | -$0.02 | -$0.05 - $0.03 | -350.00% | Miss | -181.8% | 5 | 0 up, 0 down | Nov 9, 2023 | $3.90M |
| Jun 30, 2023 | -$0.02 | -$0.08 | -$0.11 - -$0.03 | +75.00% | Beat | -109.5% | 5 | 0 up, 0 down | Aug 3, 2023 | $4.53M |
| Mar 31, 2023 | -$0.12 | $0.13 | $0.07 - $0.17 | -192.31% | Miss | -112.4% | 5 | 0 up, 0 down | May 3, 2023 | $3.41M |
| Dec 31, 2022 | $0.17 | $0.23 | $0.19 - $0.30 | -26.09% | Miss | -46.9% | 5 | 3 up, 0 down | Feb 9, 2023 | $13.10M |
| Sep 30, 2022 | $0.11 | $0.13 | $0.05 - $0.19 | -15.38% | Miss | +1000.0% | 5 | 0 up, 0 down | Nov 3, 2022 | $9.01M |
| Jun 30, 2022 | $0.21 | $0.13 | N/A | +61.54% | Beat | N/A | N/A | 0 up, 0 down | Aug 4, 2022 | $12.08M |
| Mar 31, 2022 | $0.97 | $0.40 | $0.03 - $0.80 | +142.50% | Beat | N/A | 5 | 0 up, 0 down | May 5, 2022 | $10.34M |
| Dec 31, 2021 | $0.32 | $0.16 | $0.10 - $0.22 | +100.00% | Beat | +1500.0% | 6 | 0 up, 0 down | Feb 10, 2022 | $13.03M |
| Sep 30, 2021 | $0.01 | -$0.02 | -$0.07 - $0.02 | +150.00% | Beat | N/A | 6 | N/A | Nov 4, 2021 | $5.53M |
| Jun 30, 2021 | -$0.02 | -$0.06 | -$0.08 - -$0.04 | +66.67% | Beat | N/A | 6 | N/A | Aug 5, 2021 | $5.42M |
| Mar 31, 2021 | -$0.07 | -$0.11 | -$0.13 - -$0.04 | +36.36% | Beat | N/A | 6 | N/A | May 6, 2021 | $3.07M |
| Dec 31, 2020 | $0.02 | -$0.11 | -$0.17 - -$0.08 | +118.18% | Beat | -66.7% | 6 | N/A | Feb 25, 2021 | $5.09M |
| Sep 30, 2020 | -$0.14 | -$0.14 | -$0.16 - -$0.11 | 0.00% | In line | N/A | 6 | N/A | Nov 5, 2020 | $1.62M |
| Jun 30, 2020 | -$0.16 | -$0.19 | -$0.23 - -$0.13 | +15.79% | Beat | -1700.0% | 6 | N/A | Aug 6, 2020 | $1.18M |
| Mar 31, 2020 | -$0.22 | -$0.07 | -$0.12 - -$0.03 | -214.29% | Miss | N/A | 6 | N/A | May 7, 2020 | $1.68M |
| Dec 31, 2019 | $0.06 | $0.03 | $0.00 - $0.06 | +100.00% | Beat | +500.0% | 6 | N/A | Feb 13, 2020 | $8.51M |
| Sep 30, 2019 | -$0.04 | -$0.03 | -$0.07 - $0.02 | -33.33% | Miss | N/A | 6 | N/A | Nov 6, 2019 | $5.84M |
| Jun 30, 2019 | $0.01 | -$0.04 | -$0.14 - $0.00 | +125.00% | Beat | N/A | 7 | N/A | Aug 8, 2019 | $7.48M |
| Mar 31, 2019 | -$0.13 | -$0.03 | -$0.06 - $0.00 | -333.33% | Miss | N/A | 7 | N/A | May 9, 2019 | $5.44M |
| Dec 31, 2018 | $0.01 | -$0.01 | -$0.04 - $0.03 | +200.00% | Beat | N/A | 7 | N/A | Feb 14, 2019 | $8.08M |
| Sep 30, 2018 | -$0.03 | -$0.06 | -$0.12 - -$0.04 | +50.00% | Beat | N/A | 6 | N/A | Nov 1, 2018 | $6.33M |
| Jun 30, 2018 | -$0.04 | -$0.05 | -$0.08 - -$0.03 | +20.00% | Beat | N/A | 4 | N/A | Aug 2, 2018 | $6.06M |
| Mar 31, 2018 | -$0.08 | -$0.03 | -$0.10 - -$0.03 | -166.67% | Miss | N/A | 2 | N/A | May 3, 2018 | $5.96M |
| Dec 31, 2017 | -$0.03 | -$0.08 | -$0.08 - -$0.08 | +62.50% | Beat | -1300.0% | 2 | N/A | Feb 1, 2018 | $6.47M |
| Sep 30, 2017 | -$0.07 | -$0.07 | N/A | 0.00% | In line | N/A | N/A | N/A | Nov 2, 2017 | $4.80M |
| Jun 30, 2017 | -$0.06 | -$0.13 | N/A | +53.85% | Beat | N/A | N/A | N/A | Aug 3, 2017 | $4.97M |
| Mar 31, 2017 | -$0.12 | $0.01 | N/A | N/A | N/A | N/A | N/A | N/A | May 4, 2017 | $4.35M |
| Dec 31, 2016 | $0.00 | -$0.03 | N/A | +108.33% | Beat | N/A | N/A | N/A | Feb 2, 2017 | $4.88M |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$0.47, after $0.40 the year before. It was -$0.03 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$0.47 | -217.5% |
| Dec 31, 2024 | $0.40 | +1233.3% |
| Dec 31, 2023 | $0.03 | -97.9% |
| Dec 31, 2022 | $1.46 | +508.3% |
| Dec 31, 2021 | $0.24 | N/A |
| Dec 31, 2020 | -$0.50 | N/A |
| Dec 31, 2019 | -$0.10 | N/A |
| Dec 31, 2018 | -$0.14 | N/A |
| Dec 31, 2017 | -$0.28 | N/A |
| Dec 31, 2016 | -$0.03 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 4,200 words across 7 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 4,155 | 7 | |
| 2026Q2 | Jun 30, 2026 | 3,501 | 7 | |
| 2026Q1 | Mar 31, 2026 | 3,869 | 6 | |
| 2025Q4 | Dec 31, 2025 | 3,583 | 7 | |
| 2025Q3 | Sep 30, 2025 | 4,905 | 8 | |
| 2025Q2 | Jun 30, 2025 | 5,109 | 8 | |
| 2025Q1 | Mar 31, 2025 | 4,382 | 9 | |
| 2024Q4 | Dec 31, 2024 | 5,242 | 8 |
2026Q3 Earnings Call
Opening remarks
Leigh Salvo Investor Relations Thank you. Good afternoon, and thank you all for joining today's call to discuss Sensus Healthcare's Third Quarter 2026 Financial Results. Joining me from Sensus are Joe Sardano, Chairman and Chief Executive Officer; Michael Sardano, President, Chief Commercial Officer and General Counsel; and Javier Rampolla, Chief Financial Officer. As a reminder, some of the matters that will be discussed during today's call contain forward-looking statements within the meaning of federal securities laws. All statements other than historical facts that address activities Sensus Healthcare assumes, plans, expects, believes, intends or anticipates, and other similar expressions, will, should or may occur in the future are forward-looking statements. The forward-looking statements are management's beliefs based on currently available information as of the date of this conference call, November 12, 2026. Sensus Healthcare undertakes no obligation to revise or update any forward-looking statements, except as required by law. All forward-looking statements are subject to risks and uncertainties as described in the company's Forms 10-K, 10-Q and other SEC filings. During today's call, references will be made to certain non-GAAP financial measures. Sensus believes these measures provide useful information for investors, yet they should not be considered a substitute for GAAP, nor should they be reviewed as a substitute for operating results determined in accordance with GAAP. A reconciliation of non-GAAP to GAAP results is included in today's press release. With that, I'd like to turn the call over to Joe Sardano. Joe?
Joseph Sardano Chairman and Chief Executive Officer Thank you, Leigh, and good afternoon, everyone. At the beginning of this year, we laid out five priorities for Sensus: educate the market about SRT and the new reimbursement environment, accelerate customer adoption, expand recurring revenue opportunities, broaden our commercial reach and move Sensus towards sustainable profitability. Those priorities have not changed. I want to take a minute to start with the bigger picture because it's important to understand what we're building at Sensus. For decades, surgery, including Mohs surgery, has been a primary treatment option for non-melanoma skin cancer. Mohs is an effective and well-established procedure, but surgery isn't the right choice for every patient. Many patients want to avoid cutting, stitches, scarring or the recovery associated with surgery, particularly when the cancer is in a cosmetically sensitive area. SRT gives physicians and patients another option. It's a noninvasive treatment that can address certain skin cancers without surgical excision. We believe patients should understand their treatment choices and physicians should have the technology to offer those choices when clinically appropriate. That's our vision for Sensus. We're not simply selling equipment. We're working to make SRT a more widely understood and accessible treatment option. And we're making progress.
Frequently Asked Questions About SRTS
When is Sensus Healthcare's next earnings date?
Sensus Healthcare's next earnings report is expected for Feb 10, 2027.
Did SRTS beat earnings estimates last quarter?
No. Sensus Healthcare reported EPS of -$0.09 for the quarter ended Sep 30, 2026, below the -$0.04 estimate by 107.85%.
What EPS do analysts expect from SRTS next quarter?
The consensus EPS estimate for Sensus Healthcare for the quarter ending Dec 31, 2026 is -$0.02 from 6 analysts, with estimates from -$0.04 to $0.01.
How often does SRTS beat earnings estimates?
Sensus Healthcare beat the EPS estimate in 1 of the last 8 quarters, with an average surprise of -209.56%.
SRTS pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors